PTIX Stock: Protagenic Therapeutics skyrockets 35%

Protagenic Therapeutics (PTIX) had lead the bio gains today, PTIX stock has recently surged 35% on no news released by the company.

However, a few days ago the company announced plans to up list to NASDAQ markets which could be one reason why the stock has surged today.

Another reason is that the company has also announced a public offering valued at around $13 million.

In connection with the offering, the Company has received approval to list its common stock and warrants on the Nasdaq Capital Market, with its common stock trading under the symbol “PTIX” and the warrants trading under the symbol “PTIXW”, with trading expected to begin on April 27, 2023.

Kingswood Capital Markets, division of Benchmark Investments, Inc., is acting as sole book-running manager for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as co-manager.